Pregnancy RSV vaccine slashes newborn hospital admissions by over 80%

A vaccine administered during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the timeframe when infants are most vulnerable to the virus. RSV affects roughly 50 per cent of newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.

How the vaccine safeguards at-risk babies

RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects roughly half of all newborns during their first few months of life. The virus can range from causing mild cold-like symptoms to causing severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of infants dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs working hard, as they attempt to draw enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”

The pregnancy vaccine operates by stimulating the mother’s immune system to generate defence proteins, which are then passed to the developing baby through the placenta. This mother-derived protection provides newborns with instant defence from the point of delivery, precisely when they are most vulnerable to RSV. The latest research demonstrates that protection reaches approximately 85% when the vaccine is given at least four weeks before delivery. Even shorter intervals between vaccination and birth can still provide meaningful protection, with evidence suggesting that a fortnight’s interval is sufficient to shield babies delivered prematurely. Dr Watson recommends pregnant women to have the vaccine at the recommended time, whilst noting that protection remains possible even if given later in the third trimester.

• Nearly 85% coverage when immunised four weeks before birth
• Maternal antibodies passed through placenta protect newborns from day one
• Coverage achievable with two-week gap before early delivery
• Vaccination in the third trimester still provides meaningful infant protection

Strong evidence from the latest research

The efficacy of the pregnancy RSV vaccine has been established through a comprehensive study conducted across England, reviewing data from approximately 300,000 babies born between September 2024 and March 2025. This accounts for approximately 90% of all births during that six-month timeframe, providing comprehensive and reliable evidence of the vaccine’s practical effectiveness. The study’s results have been supported by the UK Health Security Agency as showing “excellent protection” for newborns during their most critical early weeks. The scope of this study provides healthcare professionals and prospective parents with confidence in the vaccine’s established performance across diverse populations and circumstances.

The results paint a compelling picture of the vaccine’s ability to protect. More than 4,500 babies were hospitalised with RSV throughout the study period, with the overwhelming majority being infants whose mothers had not been given the vaccination. This clear distinction emphasises the vaccine’s critical role in preventing serious illness in newborns. The decrease in hospital admissions surpassing 80 per cent represents a substantial public health milestone, possibly preventing thousands of infants from experiencing the alarming and potentially severe symptoms associated with severe RSV infection. These findings support the importance of the vaccination programme launched in the UK in 2024.

Study methodology and scope

The research reviewed birth and hospital admission records from England over a six-month timeframe, capturing data on approximately 90% of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to establish clear comparisons of RSV infection levels and hospital admissions. The sizeable sample and thorough nature of the data gathering ensured that findings were statistically robust and indicative of the general population, rather than isolated cases or limited subgroups.

The study specifically monitored hospital admissions for RSV among infants born to mothers who had been given the vaccine at different timepoints before delivery. This allowed researchers to establish the minimum time required between vaccination and birth for best possible protection, as well as to determine whether protection remained meaningful with reduced timeperiods. The methodology captured actual clinical results rather than controlled laboratory conditions, providing tangible evidence of how the vaccine functions when administered across diverse clinical settings and patient circumstances throughout the final three months of pregnancy.

Understanding RSV and the dangers

Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospital admission in infants under one year of age across the United Kingdom. The virus affects approximately half of all newborns during their early months of life, with severity varying dramatically from mild cold-like symptoms to severe, life-threatening chest infections. More than 20,000 babies require intensive hospital care for RSV annually in the UK alone, placing considerable pressure on children’s wards and newborn care units during busier periods.

The infection triggers inflammation deep within the lungs and airways, making it extremely challenging for vulnerable newborns to breathe and feed adequately. Parents often witness their babies visibly struggling, their chests heaving as they try to pull adequate oxygen into their damaged lungs. Whilst most infants improve through supportive care, a limited though important number die from RSV complications yearly, making immunisation programmes a essential public health priority for protecting the most vulnerable and youngest people in our communities.

• RSV produces inflammation in lungs, causing serious respiratory problems in babies
• Nearly 50% of infants contract the infection in their first few months of life
• Symptoms span from mild colds to serious chest infections that threaten life needing hospital treatment
• Over 20,000 UK infants need serious hospital treatment for RSV each year
• A small number of babies succumb to RSV related complications each year in the UK

Take-up rates and professional guidance

Since the RSV vaccine programme launched in 2024, health officials have highlighted the significance of pregnant women getting their jab at the best time for greatest protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has underscored that timing is crucial for guaranteeing newborns receive the maximum immunity from birth. Whilst the evidence indicates that vaccination performed at least four weeks prior to delivery delivers nearly 85% protection, experts recommend women to get their vaccine as early as possible from 28 weeks of pregnancy onwards to increase the antibodies passed to their babies through the placenta.

The communication from public health bodies stays clear: pregnant women ought to prioritise vaccination during their third trimester, even if circumstances mean they cannot receive the jab at the best timing. Dr Watson has reassured expectant mothers that protection is still achievable with shorter intervals between immunisation and delivery, including even a two-week gap for those delivering slightly early. This adaptable strategy recognises the realities of pregnancy and childbirth whilst ensuring strong safeguarding for at-risk infants during their earliest and most vulnerable period when RSV poses the greatest risk of severe infection.

Regional disparities in vaccination

Whilst the RSV vaccine programme has been implemented across England, uptake rates and deployment schedules have differed across different regions and NHS trusts. Certain regions have attained higher vaccination coverage among qualifying expectant mothers, whilst others remain focused to increase awareness and availability of the jab. These regional differences reflect differences across healthcare infrastructure, engagement approaches, and local engagement efforts, though the overall statistics demonstrates consistently strong protection regardless of geographical location.

• NHS trusts rolling out diverse outreach initiatives to engage with women during pregnancy
• Inconsistencies across regions in vaccination coverage levels across England require targeted improvement
• Community health services adapting programmes to align with community needs and circumstances

Real-world impact and parent viewpoints

The vaccine’s remarkable effectiveness provides tangible benefits for families across the United Kingdom. With more than 20,000 babies admitted to hospital annually due to RSV before the introduction of this preventative solution, the 80% decrease in admissions represents thousands of infants shielded from severe infection. Parents no more face the troubling prospect of seeing their babies struggle for breath or struggle to eat, symptoms that characterise serious RSV disease. The vaccine has markedly changed the landscape of neonatal lung health, providing expectant mothers a preventative option to shield their youngest infants during those critical early months.

For families like that of Malachi, whose severe RSV infection resulted in devastating brain damage, the vaccine’s introduction carries deep personal significance. His mother’s advocacy for the jab underscores the life-altering consequences that preventable illness can inflict on young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story resonates powerfully with parents now provided with protection. The knowledge that such serious complications—hospital admission, oxygen dependency, neurological damage—are now mostly preventable has given considerable reassurance to expectant mothers navigating their late pregnancy, converting what was once an unavoidable seasonal threat into a controllable health concern.